MA45154B1 - Procédés de préparation d'oligomères - Google Patents

Procédés de préparation d'oligomères

Info

Publication number
MA45154B1
MA45154B1 MA45154A MA45154A MA45154B1 MA 45154 B1 MA45154 B1 MA 45154B1 MA 45154 A MA45154 A MA 45154A MA 45154 A MA45154 A MA 45154A MA 45154 B1 MA45154 B1 MA 45154B1
Authority
MA
Morocco
Prior art keywords
oligomer
oligomers
processes
preparation
scaling
Prior art date
Application number
MA45154A
Other languages
English (en)
Other versions
MA45154A (fr
Inventor
Bao Cai
Mitchell MARTINI
Ross SHIMABUKU
Katie THOMAS
Diane Elizabeth Frank
Richard K. Bestwick
Original Assignee
Sarepta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics, Inc. filed Critical Sarepta Therapeutics, Inc.
Publication of MA45154A publication Critical patent/MA45154A/fr
Publication of MA45154B1 publication Critical patent/MA45154B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

L'invention concerne des procédés de préparation d'un oligomère (par exemple, un oligomère morpholino). Les procédés de synthèse décrits dans l'invention peuvent être avantageux pour la mise à l'échelle de la synthèse d'oligomères tout en maintenant le rendement global et la pureté d'un oligomère synthétisé.
MA45154A 2016-05-24 2017-05-24 Procédés de préparation d'oligomères MA45154B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662356923P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US201662357166P 2016-06-30 2016-06-30
US201662357072P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/034235 WO2017205496A1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
EP17731336.8A EP3464305B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères

Publications (2)

Publication Number Publication Date
MA45154A MA45154A (fr) 2019-04-10
MA45154B1 true MA45154B1 (fr) 2024-11-29

Family

ID=59078165

Family Applications (2)

Application Number Title Priority Date Filing Date
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45154A MA45154B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Country Status (21)

Country Link
US (2) US10875880B2 (fr)
EP (2) EP3464305B1 (fr)
JP (2) JP7008642B2 (fr)
KR (1) KR102506298B1 (fr)
CN (1) CN109563114B (fr)
AU (1) AU2017269355B2 (fr)
BR (2) BR112018074346B1 (fr)
CA (1) CA3025339A1 (fr)
CO (1) CO2018013838A2 (fr)
DK (1) DK3464305T3 (fr)
ES (1) ES2993738T3 (fr)
FI (1) FI3464305T3 (fr)
HR (1) HRP20241428T1 (fr)
IL (1) IL263149B2 (fr)
MA (2) MA49775A (fr)
MD (1) MD3464305T2 (fr)
MX (2) MX384727B (fr)
SA (1) SA518400500B1 (fr)
SG (1) SG10202101830WA (fr)
TW (2) TWI801843B (fr)
WO (1) WO2017205496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SI3464306T1 (sl) 2016-05-24 2024-08-30 Sarepta Therapeutics, Inc. Postopki za pripravo fosforodiamidatnih morfolino oligomerov
MX384727B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
JP7022078B2 (ja) * 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
MX2018014160A (es) * 2016-06-30 2019-04-01 Sarepta Therapeutics Inc Procesos para preparar oligomeros de morfolino fosforodiamidato.
US20200362339A1 (en) * 2017-09-25 2020-11-19 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
US20210102205A1 (en) * 2018-04-26 2021-04-08 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy
WO2024163762A2 (fr) * 2023-02-01 2024-08-08 Alnylam Pharmaceuticals, Inc. Cycle à six chaînons contenant des oligomères

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
EP0216860B1 (fr) 1985-03-15 1992-10-28 SUMMERTON, James Polymeres stereoreguliers de liaison a un polynucleotide
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
WO1990002749A1 (fr) 1988-09-01 1990-03-22 Forskningscenter Risø Procede de synthese de peptides et support solide de realisation dudit procede
HUT76280A (en) 1993-12-29 1997-07-28 Fujisawa Pharmaceutical Co Pyrazolopyridine derivatives, pharmaceutical compositions containing them, process for proiducing them and their use
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
WO2001083740A2 (fr) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Composition anti-sens a region d'epissage et methode associee
WO2003020739A2 (fr) 2001-09-04 2003-03-13 Exiqon A/S Compositions d'acides nucleiques verrouilles et utilisations
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
WO2004044140A2 (fr) 2002-11-05 2004-05-27 Isis Pharmaceticals, Inc. Composes oligomeres 2'-substitues et compositions destinees a etre utilisees dans des modulations genetiques
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
DK1766010T3 (da) 2004-06-28 2011-06-06 Univ Western Australia Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
LT2735568T (lt) * 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
EP2207779B1 (fr) * 2007-11-15 2014-04-09 Sarepta Therapeutics, Inc. Procédé de synthèse d'oligomères morpholino
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
IL313162A (en) 2008-10-24 2024-07-01 Sarepta Therapeutics Inc Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
DK2417257T3 (da) 2009-04-10 2016-06-06 Ass Inst De Myologie Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
KR20230137491A (ko) 2009-11-12 2023-10-04 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
TWI463423B (zh) 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
KR102182663B1 (ko) * 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CA2813183C (fr) 2010-09-30 2017-09-19 Nippon Shinyaku Co., Ltd. Derive d'acide morpholino nucleique
CA2826836A1 (fr) * 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Oligonucleotides antisens
CN103889999B (zh) 2011-08-23 2021-06-01 皇家学习促进学会/麦吉尔大学 用于合成寡核糖核苷酸的离子标记
PL2581448T3 (pl) 2011-10-13 2015-08-31 Association Inst De Myologie Tricyklo-tiofosforanowy DNA
BR112014011875B1 (pt) 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
CA2857664A1 (fr) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Oligonucleotides antisens ciblant dans le smn2 pre-arnm pour l'utilisation dans une inclusion exon induite dans atrophie musculaire vertebrale
CA2861247C (fr) * 2011-12-28 2021-11-16 Nippon Shinyaku Co., Ltd. Acide nucleique antisens
EP2820155B1 (fr) 2012-02-28 2017-07-26 Population Genetics Technologies Ltd. Procédé de fixation d'une contre-séquence à un échantillon d'acides nucléiques
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
WO2014153240A2 (fr) * 2013-03-14 2014-09-25 Sarepta Therapeutics, Inc. Compositions de sauts d'exon pour le traitement de la dystrophie musculaire
KR20230116945A (ko) * 2013-03-14 2023-08-04 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
KR20150133768A (ko) 2013-03-15 2015-11-30 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 개선된 조성물
JP6477464B2 (ja) * 2013-05-24 2019-03-06 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SI3464306T1 (sl) * 2016-05-24 2024-08-30 Sarepta Therapeutics, Inc. Postopki za pripravo fosforodiamidatnih morfolino oligomerov
MX384727B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
DK3554553T3 (da) 2016-12-19 2022-09-19 Sarepta Therapeutics Inc Exon-overspringnings-oligomerkonjugat til muskeldystrofi
MD3554552T2 (ro) 2016-12-19 2022-12-31 Sarepta Therapeutics Inc Conjugați oligomeri de omitere a exonilor pentru distrofie musculară
MD3554554T2 (ro) 2016-12-19 2022-12-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии

Also Published As

Publication number Publication date
US20210198296A1 (en) 2021-07-01
IL263149B2 (en) 2023-05-01
KR20190015311A (ko) 2019-02-13
FI3464305T3 (fi) 2024-10-30
SA518400500B1 (ar) 2022-09-01
IL263149A (en) 2019-01-31
AU2017269355A1 (en) 2019-01-17
ES2993738T3 (en) 2025-01-08
US20200040020A1 (en) 2020-02-06
JP2019518832A (ja) 2019-07-04
MD3464305T2 (ro) 2025-01-31
BR112018074346B1 (pt) 2023-01-03
AU2017269355B2 (en) 2021-04-15
CN109563114A (zh) 2019-04-02
JP2021176967A (ja) 2021-11-11
MA49775A (fr) 2020-06-10
HRP20241428T1 (hr) 2025-01-03
EP3464305A1 (fr) 2019-04-10
DK3464305T3 (da) 2024-10-28
MX2021008539A (es) 2022-10-18
MX384727B (es) 2025-03-14
JP7008642B2 (ja) 2022-01-25
IL263149B1 (en) 2023-01-01
KR102506298B1 (ko) 2023-03-06
EP3464305B1 (fr) 2024-08-21
BR122022014984B1 (pt) 2024-03-05
MA45154A (fr) 2019-04-10
MX2018014472A (es) 2019-05-23
TWI738784B (zh) 2021-09-11
WO2017205496A1 (fr) 2017-11-30
US10875880B2 (en) 2020-12-29
TWI801843B (zh) 2023-05-11
SG10202101830WA (en) 2021-04-29
BR112018074346A2 (pt) 2019-03-06
CN109563114B (zh) 2022-08-12
CO2018013838A2 (es) 2019-01-18
US11384105B2 (en) 2022-07-12
TW201806962A (zh) 2018-03-01
EP3564248A1 (fr) 2019-11-06
CA3025339A1 (fr) 2017-11-30
TW202200599A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
MA45155B1 (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45154B1 (fr) Procédés de préparation d'oligomères
MX390906B (es) Procesos para preparar oligómeros de morfolino fosforodiamidato.
MA46452B1 (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
WO2019207308A3 (fr) Procédés
ZA202403308B (en) An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide
MA31759B1 (fr) Compose amide
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
WO2016141296A8 (fr) Inhibiteurs de kinases tricycliques de melk et procédés d'utilisation
MX393879B (es) Métodos de preparación de niraparib.
BR0008693A (pt) Sìntese regio-seletiva de derivados de dtpa
WO2018039629A3 (fr) Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
MX2025000971A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxilico
WO2017112809A8 (fr) Système et procédé de synthèse de peptides gap en phase solution
MA68842B1 (fr) Procédé de conjugaison de cys-mabs
MX392700B (es) Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
MX2021007505A (es) Síntesis de 3-metil-1,2,4-tiadiazol-5-carbohidrazida o de su forma deuterada con metil-d3.
MA46548A (fr) Fsh pour le traitement de l'infertilité
MY195119A (en) Method For Purifying Isobutene from a C4 Stream and Process System Therefor
MX2018014160A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
MX395643B (es) Proceso para preparar fenilalcanos sustituidos.
MA56055A (fr) Procédés de préparation d'acide 5-bromo-2-(3chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylique
NO20060417L (no) Fremgangsmate til fremstilling av 1-okten fra krakk-C4
EP4081203A4 (fr) Spectroscopie ftnir pour le suivi de la réaction de synthèse de l'acrylamide
CL2014001043A1 (es) Procedimiento para preparar un compuesto intermediario en la ruta de sintesis de tmc 435, inhibidor de proteasa, útil en el tratamiento de la hepatitis c.